Chengdu Shengnuo Biopharm Co Ltd

Chengdu Shengnuo Biopharm is a leading peptide manufacturer in China, holding 5 US-DMFs for peptide APIs — liraglutide, bivalirudin, eptifibatide, icatibant and octreotide — with additional DMFs planned for linaclotide, degarelix, teriparatide, ziconotide, exenatide and ganirelix, plus several Chinese GMP APIs including atosiban, carbetocin, enfuvirtide, thymalfasin, somatostatin, thymopentin and levosimendan. Founded in October 2004 as a subsidiary of Chengdu Shengnuo Tech Development, the company holds 50 key technologies for large-scale peptide drug production via solid-phase chemistry, with capabilities spanning product development, technology transfer, technical services and large-scale multi-kilogram batch production.